Total submissions: 1
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Women's Health and Genetics/Laboratory Corporation of America, |
RCV001193641 | SCV001362609 | pathogenic | Fabry disease | 2019-06-19 | criteria provided, single submitter | clinical testing | Variant summary: GLA c.406G>T (p.Asp136Tyr) results in a non-conservative amino acid change in the encoded protein sequence. Five of five in-silico tools predict a damaging effect of the variant on protein function. The variant was absent in 183470 control chromosomes (gnomAD). c.406G>T has been reported in the literature in a large family with multiple individuals affected with Fabry Disease (Vedder_2007, Aerts_2007). Residual activity was found to be 0% (Vedder_2007). No clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar after 2014. Based on the evidence outlined above, the variant was classified as pathogenic. |